Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia

Clinical Neurophysiology

Volumn 117, Issue 10, 2006, Pages 2204-2210

  Nardone, R ^a   Marth, R ^a   Ausserer, H ^a   Bratti, A ^a   Tezzon, F ^a  

^a Department of Neurology F Tappeiner Hospital Merano ^*  (Italy)

Author keywords

Acetylcholinesterase inhibitor; Afferent inhibition; Alzheimer's disease; Dementia; Down syndrome; Transcranial magnetic stimulation

Indexed keywords

DONEPEZIL;

ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DEMENTIAL SCALE FOR DOWN SYNDROME; DOWN SYNDROME; FEMALE; HUMAN; LATENT INHIBITION; MALE; MOTOR CORTEX; NERVE EXCITABILITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RATING SCALE; SHORT LATENCY AFFERENT INHIBITION; SINGLE DRUG DOSE; TRANSCRANIAL MAGNETIC STIMULATION;

ADULT; ALZHEIMER DISEASE; BRAIN; CHOLINESTERASE INHIBITORS; DOWN SYNDROME; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEURAL INHIBITION; PIPERIDINES; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 33748300905     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2006.07.134     Document Type: Article

References (43)

1. Alexander G.E., Chen K., Pietrini P., Rapaport S.I., and Reiman E.M. Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. Neuroreport 8 (1997) 1835-1840
2. Casanova M.F., Walker L.C., Whitehouse P.J., and Price D.L. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol 18 (1985) 310-313
3. Chapman R.S. Language development in children and adolescents with Down syndrome. In: Fletcher P., and MacWhinney B. (Eds). Handbook of child language (1995), Blackwell, Oxford 641-663
4. Daskalakis Z.J., Molnar G.F., Christensen B.K., Sailer A., Fitzgerald P.B., and Chen R. An automated method to determine the transcranial magnetic stimulation-induced contralateral silent period. Clin Neurophysiology 114 (2003) 938-944
5. DeLa Torre R., Casado A., Lopez-Fernandez E., Carrascosa D., Ramirez V., and Saez J. Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia 52 (1996) 871-873
6. Di Lazzaro V., Oliviero A., Profice P., Pennini M.A., Di Giovanni S., Zito G., et al. Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res 135 (2000) 455-461
7. Di Lazzaro V., Oliviero A., Tonali P.A., Marra C., Daniele A., Proficue P., et al. Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology 13 (2002) 392-397
8. Di Lazzaro V., Oliviero A., Pilato F., Saturno E., Dileone M., Marra C., et al. Neurophysiological predictors of long term response to AchE inhibitors in AD patients. J Neurol Neurosurg Psychiatry 76 (2005) 1064-1069
9. Doody R.S. Current treatment for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry 64 (2003) 11-17
10. Engidawork E., and Lubec G. Protein expression in Down syndrome brain. Amino Acids 21 (2001) 331-361
11. Evenhuis H.M. The natural history of dementia in Down's syndrome. Arch Neurol 47 (1990) 263-267
12. Gedye A. Manual for the Dementia Scale for Down Syndrome: Geyde Research and Consulting, Vancouver, 1995.
13. Hallett M. Transcranial magnetic stimulation and the human brain. Nature 406 (2000) 147-150
14. Heller J.H., Spiridigliozzi G.A., Sullivan J.A., Doraiswamy M.P., Krishnan R.R., and Kishnani P.S. Donezepil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open study. Am J Med Genet 116 (2003) 111-116
15. Heller J.H., Spiridigliozzi G.A., Doraiswamy M.P., Sullivan J.A., Crissman B.G., and Kishnani P.S. Donezepil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. Am J Med Genet 130 (2004) 325-326
16. Hof P.R., Bouras C., Perl D.P., Sparks D.L., Metha N., and Morrison J.H. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol 52 (1995) 379-391
17. Holland A.J., Hon J., Huppert F.A., and Stevens F. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J Intellect Disabil Res 44 (2000) 138-146
18. Isacson O., Seo H., Lin L., Albeck D., and Granholm A.C. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and Ach. Trends Neurosci 2582 (2002) 79-84
19. Johnson N., Fahey C., Chocoine B., Chong G., and Gitelman D. Effects of donezepil on cognitive functioning in Down syndrome. Am J Ment Retard 108 (2003) 367-372
20. Kishnani P.S., Sullivan J.A., Walter B.K., Spiridigliozzi G.A., Doraiswamy P.M., and Krishnan K.R.R. Cholinergic therapy for Down's syndrome. Lancet 353 (1999) 1064-1065
21. Kondoh T., Amamoto N., Doi T., Hamada H., Ogawa Y., Hakashima M., et al. Dramatic improvement in Down syndrome-associated cognitive impairment with donezepil. Ann Pharmacother 39 (2005) 563-566
22. Kujirai T., Caramia M.D., Rothwell J.C., et al. Cortico-cortical inhibition in human motor cortex. J Physiol 471 (1993) 501-520
23. Lai F., and Williams R.S. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 46 (1989) 849-853
24. Lott I.T., Osann K., Doran E., and Nelson L. Down syndrome and Alzheimer disease: response to donezepil. Arch Neurol 59 (2002) 1133-1136
25. Mann D.M., Yates P.O., Marcyniuk B., and Ravindra C.R. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res 29 (1985) 125-135
26. Mann D.M., and Esiri M.M. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89 (1989) 169-179
27. McLendon B., and Doraiswamy P.M. Defining meaningful change in Alzheimer's disease trials: the donezepil experience. J Geriatr Psychiatry Neurol 12 (1999) 39-48
28. Mufson E.J., Cochran E., Benzing W., and Kordower J.H. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2), and bed nucleus of the stria terminalis in aging, Alzheimer's disease, and Down's syndrome. Dementia 4 (1993) 237-250
29. Oliver C., Crayton L., Holland A., Hall S., and Bradbury J. A four year perspective study of age-related cognitive change in adults with Down's syndrome. Psychol Med 28 (1998) 1365-1377
30. Prasher V.P. Age-specific prevalence, thyroid dysfunction and depressive symptomatology in adults with Down syndrome and dementia. Int J Geriatr Psychiatry 10 (1995) 25-31
31. Prasher V.P., Huxley A., and Haque M.S. Down Syndrome Ageing Study Group, 2002. A 24-week, double-blind, placebo-controlled trial of donezepil in patients with Down syndrome and Alzheimer's disease-pilot study. Int J Geriatr Psychiatry 17 (2002) 270-278
32. Raskind M.A., Sadowski C.H., Sigmund W.R., Beitler P.J., and Auster S.B. Effects of tacrine on language, praxis and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 54 (1997) 836-840
33. Rogers S.L., and Friedhoff L.T. Pharmacokinetic and pharmacodynamic profile of donezepil HCl following single oral doses. Br J Clin Pharmacol 46 (1998) 1-6
34. Rondal J.A., and Comblain A. Language in adults with Down syndrome. Down syndrome Res Pract 4 (1996) 3-14
35. Rossini P., Barker A., Berardelli A., Caramia M.D., Caruso G., Cracco R.Q., et al. Non invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application: report of IFCN committee. Electroencephalogr Clin Neurophysiol 91 (1994) 79-92
36. Rothwell J.C. Techniques of transcranial magnetic stimulation. In: Boniface S.J., and Ziemann U. (Eds). Plasticity in human nervous system. Investigations with transcranial magnetic stimulation (2003), Cambridge University Press 26-61
37. Shapiro M.B., Haxby J.V., and Grady C.L. Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology. Neurobiol Aging 13 (1992) 23-734
38. Tokimura H., Di Lazzaro V., Tokimura Y., Oliviero A., Profice P., Insola A., et al. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol 523 (2000) 503-513
39. Wenk G., McGann K., Mencarelli A., Hauss-Wegrzyniak B., Del Soldato P., and Fiorucci S. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur J Pharmacol 402 (2002) 77-85
40. Wisniewski K.E., and Wisniewski H.M. Age associated changes and dementia in Down's syndrome. In: Reisberg B. (Ed). Textbook of Alzheimer's disease (1983), Free Press, New York 319-326
41. Wisniewski K.E., Wisniewski H.M., and Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease and Down's syndrome. Ann Neurol 17 (1985) 278-282
42. Wisniewski H.M., Wegiel J., and Popovitch E.R. Age-associated development of diffuse and thioflavine-S-positive plaques in Down's syndrome. Dev Brain Dysfunct 7 (1994) 330-339
43. Ziemann U. Assessment of motor cortex and descending motor pathways. In: Brown W.F., Bolton C.F., and Aminoff M.J. (Eds). Neuromuscular function and disease. Basis, clinical and electrodiagnostic aspects vol. 1 (2002), Philadelphia, Saunders 189-221